Literature DB >> 11911268

Modulation of CD99/MIC2 expression of human AHTO-7 osteoblasts by carcinoma cell line-conditioned media.

D Hamilton1, R Mallinger, H Millesi, A Engel, G Baumgartner, M Raderer.   

Abstract

BACKGROUND: Prostate cancer metastases induce a predominantly osteoblastic response in bone tissue, resulting in new bone formation and associated morbidity; however, the mechanisms of these tumor-host responses are not fully understood.
MATERIALS AND METHODS: Supernatants of prostate (PC3, DU145, LNCaP), breast (BT20, ZR-75-1), colon (SW620, Colo 320DM), pancreatic (ASPC1, Capan-1), renal cell (ACHN) and hepatoma (HepG2) cell lines were tested for their capacity to modulate proliferation, activity of alkaline phosphatase (ALP) and CD99/MIC2 expression in AHTO-7 (large T antigen transfected human trabecular osteoblasts) cells in vitro.
RESULTS: Osteoblastic stimulation is not restricted to prostate cancer derived conditioned media CM and high activity is found in CM from Capan-1, HepG2 and ACHN lines. Furthermore these CM down-regulate the expression of the CD99/MIC2 antigen in comparison to medium by AHTO-7 cells as detected by HBA-71 immunofluorescence, with the exception of prostate cancer-derived CM. Induction of the differentiation marker ALP was detected in response to CM derived from Capan-1, BT-20 and Colo320DM. Stimulation of the proliferation of AHTO-7 cells (105-138% of control), induction of ALP (1.17-5.29-fold) and down-regulation of CD99 (13.6-57.5%) exhibited no correlation. CM derived from PC3 and LNCaP metastatic prostate cancer cell lines specifically resulted in the retention/stimulation of the expression of CD99/MIC2 in AHTO-7 cells in contrast to all other cell lines tested.
CONCLUSION: The CD99/MIC2 antigen, which is expressed on human osteoblasts and osteosarcoma cells, seems to constitute a new and independent response marker of osteoblasts in the triggering of osteoblastic reaction by prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11911268

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  CD99 acts as an oncosuppressor in osteosarcoma.

Authors:  Maria Cristina Manara; Ghislaine Bernard; Pier-Luigi Lollini; Patrizia Nanni; Monia Zuntini; Lorena Landuzzi; Stefania Benini; Giovanna Lattanzi; Marika Sciandra; Massimo Serra; Mario Paolo Colombo; Alain Bernard; Piero Picci; Katia Scotlandi
Journal:  Mol Biol Cell       Date:  2006-01-18       Impact factor: 4.138

2.  Human myeloma cell lines induce osteoblast downregulation of CD99 which is involved in osteoblast formation and activity.

Authors:  Angela Oranger; Giacomina Brunetti; Claudia Carbone; Graziana Colaianni; Teresa Mongelli; Isabella Gigante; Roberto Tamma; Giorgio Mori; Adriana Di Benedetto; Marika Sciandra; Selena Ventura; Katia Scotlandi; Silvia Colucci; Maria Grano
Journal:  J Immunol Res       Date:  2015-04-27       Impact factor: 4.818

3.  CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2.

Authors:  Marika Sciandra; Maria Teresa Marino; Maria Cristina Manara; Clara Guerzoni; Maria Grano; Angela Oranger; Enrico Lucarelli; Pier-Luigi Lollini; Barbara Dozza; Loredana Pratelli; Maria Flavia Di Renzo; Mario Paolo Colombo; Piero Picci; Katia Scotlandi
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.